|
||||||
|
 | Fusion Gene Summary |
| Fusion Gene ORF analysis |
| Fusion Genomic Features |
| Fusion Protein Features |
| Fusion Gene Sequence |
| Fusion Gene PPI analysis |
| Related Drugs |
| Related Diseases |
Fusion gene:ENO1-ENO3 (FusionGDB2 ID:26553) |
Fusion Gene Summary for ENO1-ENO3 |
 Fusion gene summary |
| Fusion gene information | Fusion gene name: ENO1-ENO3 | Fusion gene ID: 26553 | Hgene | Tgene | Gene symbol | ENO1 | ENO3 | Gene ID | 2023 | 2027 |
| Gene name | enolase 1 | enolase 3 | |
| Synonyms | ENO1L1|HEL-S-17|MPB1|NNE|PPH | GSD13|MSE | |
| Cytomap | 1p36.23 | 17p13.2 | |
| Type of gene | protein-coding | protein-coding | |
| Description | alpha-enolasec-myc promoter-binding protein-12-phospho-D-glycerate hydro-lyaseMYC promoter-binding protein 1alpha enolase like 1enolase 1, (alpha)enolase-alphaepididymis secretory protein Li 17non-neural enolasephosphopyruvate hydrataseplasminog | beta-enolase2-phospho-D-glycerate hydrolyaseenolase 3 (beta, muscle)muscle enriched enolasemuscle-specific enolaseskeletal muscle enolase | |
| Modification date | 20200320 | 20200313 | |
| UniProtAcc | P06733 | P13929 | |
| Ensembl transtripts involved in fusion gene | ENST00000234590, | ENST00000323997, ENST00000519584, ENST00000518175, | |
| Fusion gene scores | * DoF score | 31 X 31 X 10=9610 | 4 X 4 X 3=48 |
| # samples | 44 | 4 | |
| ** MAII score | log2(44/9610*10)=-4.44896100213645 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(4/48*10)=-0.263034405833794 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
| Context | PubMed: ENO1 [Title/Abstract] AND ENO3 [Title/Abstract] AND fusion [Title/Abstract] | ||
| Most frequent breakpoint | ENO1(8926350)-ENO3(4857068), # samples:1 | ||
| Anticipated loss of major functional domain due to fusion event. | |||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Hgene | ENO1 | GO:0000122 | negative regulation of transcription by RNA polymerase II | 2005901 |
| Hgene | ENO1 | GO:0030308 | negative regulation of cell growth | 10082554 |
| Hgene | ENO1 | GO:0045892 | negative regulation of transcription, DNA-templated | 10082554 |
| Hgene | ENO1 | GO:0061621 | canonical glycolysis | 29775581 |
| Hgene | ENO1 | GO:1903298 | negative regulation of hypoxia-induced intrinsic apoptotic signaling pathway | 15459207 |
| Hgene | ENO1 | GO:2001171 | positive regulation of ATP biosynthetic process | 15459207 |
| Fusion gene breakpoints across ENO1 (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
| Fusion gene breakpoints across ENO3 (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
| Fusion gene information from two resources (ChiTars 5.0 and ChimerDB 4.0) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Source | Disease | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| ChiTaRS5.0 | N/A | AI557505 | ENO1 | chr1 | 8926350 | - | ENO3 | chr17 | 4857068 | + |
Top |
Fusion Gene ORF analysis for ENO1-ENO3 |
| Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| intron-3CDS | ENST00000234590 | ENST00000323997 | ENO1 | chr1 | 8926350 | - | ENO3 | chr17 | 4857068 | + |
| intron-3CDS | ENST00000234590 | ENST00000519584 | ENO1 | chr1 | 8926350 | - | ENO3 | chr17 | 4857068 | + |
| intron-3CDS | ENST00000234590 | ENST00000518175 | ENO1 | chr1 | 8926350 | - | ENO3 | chr17 | 4857068 | + |
| ORFfinder result based on the fusion transcript sequence of in-frame fusion genes. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
| DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
Top |
Fusion Genomic Features for ENO1-ENO3 |
| FusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints. |
| Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | 1-p | p (fusion gene breakpoint) |
| Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions. We integrated a total of 44 different types of human genomic feature loci information across five big categories including virus integration sites, repeats, structural variants, chromatin states, and gene expression regulation. More details are in help page. |
| Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions that are ovelapped with the top 1% feature importance score regions. More details are in help page. |
Top |
Fusion Protein Features for ENO1-ENO3 |
| Go to FGviewer for the breakpoints of :-: - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. |
 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| ENO1 | ENO3 |
| FUNCTION: Glycolytic enzyme the catalyzes the conversion of 2-phosphoglycerate to phosphoenolpyruvate (PubMed:29775581, PubMed:1369209). In addition to glycolysis, involved in various processes such as growth control, hypoxia tolerance and allergic responses (PubMed:2005901, PubMed:10802057, PubMed:12666133, PubMed:29775581). May also function in the intravascular and pericellular fibrinolytic system due to its ability to serve as a receptor and activator of plasminogen on the cell surface of several cell-types such as leukocytes and neurons (PubMed:12666133). Stimulates immunoglobulin production (PubMed:1369209). {ECO:0000269|PubMed:10802057, ECO:0000269|PubMed:12666133, ECO:0000269|PubMed:1369209, ECO:0000269|PubMed:2005901, ECO:0000269|PubMed:29775581}.; FUNCTION: MBP1 binds to the myc promoter and acts as a transcriptional repressor. May be a tumor suppressor. {ECO:0000269|PubMed:10082554}. | FUNCTION: Appears to have a function in striated muscle development and regeneration. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
| - In-frame and retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| - In-frame and not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
Fusion Gene Sequence for ENO1-ENO3 |
| For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
Top |
Fusion Gene PPI Analysis for ENO1-ENO3 |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in |
| Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
| Hgene | Hgene's interactors | Tgene | Tgene's interactors |
| - Retained PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
| - Retained PPIs, but lost function due to frame-shift fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
Related Drugs for ENO1-ENO3 |
| Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.8 2021-05-08) |
| Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
| Hgene | ENO1 | P06733 | DB14548 | Zinc sulfate, unspecified form | Binder | Small molecule | Approved|Experimental |
| Hgene | ENO1 | P06733 | DB14548 | Zinc sulfate, unspecified form | Binder | Small molecule | Approved|Experimental |
| Hgene | ENO1 | P06733 | DB14548 | Zinc sulfate, unspecified form | Binder | Small molecule | Approved|Experimental |
| Hgene | ENO1 | P06733 | DB14548 | Zinc sulfate, unspecified form | Binder | Small molecule | Approved|Experimental |
| Hgene | ENO1 | P06733 | DB01593 | Zinc | Small molecule | Approved|Investigational | |
| Hgene | ENO1 | P06733 | DB01593 | Zinc | Small molecule | Approved|Investigational | |
| Hgene | ENO1 | P06733 | DB01593 | Zinc | Small molecule | Approved|Investigational | |
| Hgene | ENO1 | P06733 | DB01593 | Zinc | Small molecule | Approved|Investigational | |
| Hgene | ENO1 | P06733 | DB09130 | Copper | Small molecule | Approved|Investigational | |
| Hgene | ENO1 | P06733 | DB09130 | Copper | Small molecule | Approved|Investigational | |
| Hgene | ENO1 | P06733 | DB09130 | Copper | Small molecule | Approved|Investigational | |
| Hgene | ENO1 | P06733 | DB09130 | Copper | Small molecule | Approved|Investigational | |
| Hgene | ENO1 | P06733 | DB14487 | Zinc acetate | Small molecule | Approved|Investigational | |
| Hgene | ENO1 | P06733 | DB14487 | Zinc acetate | Small molecule | Approved|Investigational | |
| Hgene | ENO1 | P06733 | DB14487 | Zinc acetate | Small molecule | Approved|Investigational | |
| Hgene | ENO1 | P06733 | DB14487 | Zinc acetate | Small molecule | Approved|Investigational | |
| Hgene | ENO1 | P06733 | DB14533 | Zinc chloride | Binder | Small molecule | Approved|Investigational |
| Hgene | ENO1 | P06733 | DB14533 | Zinc chloride | Binder | Small molecule | Approved|Investigational |
| Hgene | ENO1 | P06733 | DB14533 | Zinc chloride | Binder | Small molecule | Approved|Investigational |
| Hgene | ENO1 | P06733 | DB14533 | Zinc chloride | Binder | Small molecule | Approved|Investigational |
Top |
Related Diseases for ENO1-ENO3 |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
| Hgene | ENO1 | C0019193 | Hepatitis, Toxic | 2 | CTD_human |
| Hgene | ENO1 | C0152013 | Adenocarcinoma of lung (disorder) | 2 | CTD_human |
| Hgene | ENO1 | C0860207 | Drug-Induced Liver Disease | 2 | CTD_human |
| Hgene | ENO1 | C1262760 | Hepatitis, Drug-Induced | 2 | CTD_human |
| Hgene | ENO1 | C3658290 | Drug-Induced Acute Liver Injury | 2 | CTD_human |
| Hgene | ENO1 | C4277682 | Chemical and Drug Induced Liver Injury | 2 | CTD_human |
| Hgene | ENO1 | C4279912 | Chemically-Induced Liver Toxicity | 2 | CTD_human |
| Hgene | ENO1 | C0001418 | Adenocarcinoma | 1 | CTD_human |
| Hgene | ENO1 | C0001787 | Osteoporosis, Age-Related | 1 | CTD_human |
| Hgene | ENO1 | C0002395 | Alzheimer's Disease | 1 | CTD_human |
| Hgene | ENO1 | C0003873 | Rheumatoid Arthritis | 1 | CTD_human |
| Hgene | ENO1 | C0006142 | Malignant neoplasm of breast | 1 | CTD_human |
| Hgene | ENO1 | C0007097 | Carcinoma | 1 | CTD_human |
| Hgene | ENO1 | C0007131 | Non-Small Cell Lung Carcinoma | 1 | CTD_human |
| Hgene | ENO1 | C0007137 | Squamous cell carcinoma | 1 | CTD_human |
| Hgene | ENO1 | C0011265 | Presenile dementia | 1 | CTD_human |
| Hgene | ENO1 | C0014859 | Esophageal Neoplasms | 1 | CTD_human |
| Hgene | ENO1 | C0021364 | Male infertility | 1 | CTD_human |
| Hgene | ENO1 | C0024623 | Malignant neoplasm of stomach | 1 | CTD_human |
| Hgene | ENO1 | C0024667 | Animal Mammary Neoplasms | 1 | CTD_human |
| Hgene | ENO1 | C0024668 | Mammary Neoplasms, Experimental | 1 | CTD_human |
| Hgene | ENO1 | C0026640 | Mouth Neoplasms | 1 | CTD_human |
| Hgene | ENO1 | C0027626 | Neoplasm Invasiveness | 1 | CTD_human |
| Hgene | ENO1 | C0029408 | Degenerative polyarthritis | 1 | CTD_human |
| Hgene | ENO1 | C0029456 | Osteoporosis | 1 | CTD_human |
| Hgene | ENO1 | C0029459 | Osteoporosis, Senile | 1 | CTD_human |
| Hgene | ENO1 | C0038356 | Stomach Neoplasms | 1 | CTD_human |
| Hgene | ENO1 | C0086743 | Osteoarthrosis Deformans | 1 | CTD_human |
| Hgene | ENO1 | C0153381 | Malignant neoplasm of mouth | 1 | CTD_human |
| Hgene | ENO1 | C0205641 | Adenocarcinoma, Basal Cell | 1 | CTD_human |
| Hgene | ENO1 | C0205642 | Adenocarcinoma, Oxyphilic | 1 | CTD_human |
| Hgene | ENO1 | C0205643 | Carcinoma, Cribriform | 1 | CTD_human |
| Hgene | ENO1 | C0205644 | Carcinoma, Granular Cell | 1 | CTD_human |
| Hgene | ENO1 | C0205645 | Adenocarcinoma, Tubular | 1 | CTD_human |
| Hgene | ENO1 | C0205696 | Anaplastic carcinoma | 1 | CTD_human |
| Hgene | ENO1 | C0205697 | Carcinoma, Spindle-Cell | 1 | CTD_human |
| Hgene | ENO1 | C0205698 | Undifferentiated carcinoma | 1 | CTD_human |
| Hgene | ENO1 | C0205699 | Carcinomatosis | 1 | CTD_human |
| Hgene | ENO1 | C0276496 | Familial Alzheimer Disease (FAD) | 1 | CTD_human |
| Hgene | ENO1 | C0494463 | Alzheimer Disease, Late Onset | 1 | CTD_human |
| Hgene | ENO1 | C0520459 | Necrotizing Enterocolitis | 1 | CTD_human |
| Hgene | ENO1 | C0546126 | Acute Confusional Senile Dementia | 1 | CTD_human |
| Hgene | ENO1 | C0546837 | Malignant neoplasm of esophagus | 1 | CTD_human |
| Hgene | ENO1 | C0678222 | Breast Carcinoma | 1 | CTD_human |
| Hgene | ENO1 | C0750900 | Alzheimer's Disease, Focal Onset | 1 | CTD_human |
| Hgene | ENO1 | C0750901 | Alzheimer Disease, Early Onset | 1 | CTD_human |
| Hgene | ENO1 | C0751406 | Post-Traumatic Osteoporosis | 1 | CTD_human |
| Hgene | ENO1 | C0848676 | Subfertility, Male | 1 | CTD_human |
| Hgene | ENO1 | C0917731 | Male sterility | 1 | CTD_human |
| Hgene | ENO1 | C0948089 | Acute Coronary Syndrome | 1 | CTD_human |
| Hgene | ENO1 | C1257925 | Mammary Carcinoma, Animal | 1 | CTD_human |
| Hgene | ENO1 | C1257931 | Mammary Neoplasms, Human | 1 | CTD_human |
| Hgene | ENO1 | C1458155 | Mammary Neoplasms | 1 | CTD_human |
| Hgene | ENO1 | C1708349 | Hereditary Diffuse Gastric Cancer | 1 | CTD_human |
| Hgene | ENO1 | C2239176 | Liver carcinoma | 1 | CTD_human |
| Hgene | ENO1 | C4704874 | Mammary Carcinoma, Human | 1 | CTD_human |
| Tgene | ENO3 | C2752027 | Glycogen Storage Disease XIII | 2 | CTD_human;GENOMICS_ENGLAND;ORPHANET;UNIPROT |
| Tgene | ENO3 | C0023895 | Liver diseases | 1 | CTD_human |
| Tgene | ENO3 | C0086565 | Liver Dysfunction | 1 | CTD_human |
Copyright 2021-Present -The University of Texas Health Science Center at Houston (UTHealth)
Web File Viewing | Emergency Information |Campus Carry|Site Policies